» Articles » PMID: 35938721

Durable Response to Ivosidenib in Post-transplant Relapse and Leukemic Transformation of Myelodysplastic Syndrome with New Complex Karyotype and R132C Mutation

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2022 Aug 8
PMID 35938721
Authors
Affiliations
Soon will be listed here.
Citing Articles

Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation.

Alkhaldi H, Kharfan-Dabaja M, El Fakih R, Aljurf M Bone Marrow Transplant. 2023; 58(10):1075-1083.

PMID: 37516808 DOI: 10.1038/s41409-023-02073-6.

References
1.
Mossner M, Jann J, Wittig J, Nolte F, Fey S, Nowak V . Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016; 128(9):1246-59. DOI: 10.1182/blood-2015-11-679167. View

2.
Cazzola M . Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374. DOI: 10.1056/NEJMra1904794. View

3.
Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C . Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2018; 1(3):193-204. PMC: 5737177. DOI: 10.1182/bloodadvances.2016000760. View

4.
Jacoby M, Duncavage E, Chang G, Miller C, Shao J, Elliott K . Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018; 3(5). PMC: 5922277. DOI: 10.1172/jci.insight.98962. View

5.
Stein E, DiNardo C, Fathi A, Pollyea D, Stone R, Altman J . Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib. Blood. 2018; 133(7):676-687. PMC: 6384189. DOI: 10.1182/blood-2018-08-869008. View